上海交通大学学报（医学版）

›› 2012, Vol. 32 ›› Issue (2): 219-.doi: 10.3969/j.issn.1674-8115.2012.02.021

• 综述 • 上一篇    下一篇

糖尿病性视网膜病变抗血管内皮生长因子治疗进展

王莉莉, 刘 堃, 许 迅   

  1. 上海交通大学附属第一人民医院眼科, 上海 200080
  • 出版日期:2012-02-28 发布日期:2012-02-28
  • 作者简介:王莉莉（1986—）, 女, 博士生；电子信箱: lilywang_ophthal@163.com。
  • 基金资助:

    上海市眼底病重点实验室开放课题基金（07Z22911）

Update on anti-vascular endothelial growth factor therapy for diabetic retinopathy

WANG Li-li, LIU Kun, XU Xun   

  1. Department of Ophthalmology, the First People's Hospital, Shanghai Jiaotong University, Shanghai 200080, China
  • Online:2012-02-28 Published:2012-02-28
  • Supported by:

    Shanghai Key Laboratory for Ocular Fundus Diseases Foundation, 07Z22911

PDF (PC)

2234

摘要：

血管内皮生长因子（VEGF）在糖尿病性视网膜病变（DR）发病过程中的重要作用逐渐得到广泛而深入的认识。阻断VEGF信号转导通路上的任何环节即可抑制VEGF发挥其生物学特性，从而达到治疗目的。文章以治疗DR的抗VEGF药物的不同作用位点为分类依据，对目前处于临床或实验室研究阶段的各类药物的机制和疗效等进行综述。

关键词: 糖尿病性视网膜病变, 血管内皮生长因子, 抗血管内皮生长因子治疗

Abstract:

A comprehensive consensus has been reached that vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of diabetic retinopathy (DR). Theoretically, a block to any step of the VEGF signal pathway may interrupt the biological function of VEGF, so that the therapeutic effect can be achieved. This paper reviews the mechanisms and efficacies of different anti-VEGF drugs, either in clinical trial or laboratory research phase, that have been used in the treatment of DR.

Key words: diabetic retinopathy, vascular endothelial growth factor, anti-vascular endothelial growth factor therapy